Death ligand TRAIL induces no apoptosis but inhibits activation of human (auto)antigen-specific T cells

Journal of Immunology

Volumn 168, Issue 10, 2002, Pages 4881-4888

  Lünemann, Jan D ^a   Waiczies, Sonia ^a   Ehrlich, Stefan ^a   Wendling, Uwe ^a   Seeger, Bibiane ^a   Kamradt, Thomas ^a   Zipp, Frauke ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 0037094010     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.168.10.4881     Document Type: Article

References (38)

1. Identification and characterization of a new member of the TNF family that induces apoptosis
2. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family
3. An antagonist decoy receptor and a death domain-containing receptor for TRAIL
4. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors
5. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL
6. Expression of TRAIL receptors in human autoreactive and foreign antigen-specific T cells
7. Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity
8. 2 ligand: A novel lethal weapon against malignant glioma?
9. Safety and antitumor activity of recombinant soluble Apo2 ligand
10. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo
11. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand
12. Massive cell death induced by tumor-necrosis factor-related apoptosis-inducing ligand (TRAIL) in adult human brain tissue
13. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression
14. Roles of TNF-related apoptosis-inducing ligand in experimental autoimmune encephalomyelitis
15. Human autoreactive and foreign antigen-specific T cells resist apoptosis induced by soluble recombinant CD95 ligand
16. Myelin basic proteins
17. Diversity of the anti-T-cell receptor immune response and its implications for T-cell vaccination therapy of multiple sclerosis
18. The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells
19. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry
20. 2+ indicators with greatly improved fluorescence properties
21. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions
22. 2+ stores
23. Intracellular calcium dependence of gene expression in single T lymphocytes
24. 3+ concentrations block the calcium release-activated channel, and impair CD69 and CD25 expression in CD3- or thapsigargin-activated Jurkat cells
25. Rapid nuclear translocation and increased activity of cyclin-dependent kinase 6 after T cell activation
26. CD28 costimulation mediates T cell expansion via IL-2-independent and IL-2-dependent regulation of cell cycle progression
27. kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes
28. Kip1
29. 2 ligand/TRAIL in activation-induced death of Jurkat and human peripheral blood T cells
30. 0 T cells
31. Differential requirements for interleukin-2 distinguish the expression and activity of the cyclin-dependent kinases Cdk4 and Cdk2 in human T cells
32. Cell-cycle regulation in immunity, tolerance and autoimmunity
33. Advances in immunology: Tolerance and autoimmunity
34. 1a phase of the cell cycle
35. T cell antigen receptor signal transduction
36. Potassium and calcium channels in lymphocytes
37. Tumor necrosis factor-α, sphingomyelinase, and ceramide inhibit store-operated calcium entry in thyroid FRLT-5 cells
38. Stimulation of CD95 (Fas) blocks T lymphocyte calcium channels through sphingomyelinase and sphingolipids